Diffuse midline glioma with H3K27 alteration in adults: a clinicopathological analysis.
10.3760/cma.j.cn112151-20220926-00810
- Author:
Qin Yi YANG
1
;
Ming Na LI
1
;
Tian Yu CHEN
1
;
Chong LIU
1
;
Xiao LI
1
;
Zhu Mei SHI
2
;
Min Hong PAN
3
Author Information
1. Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
2. Department of Neurosurgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
3. Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China Collaborative Innovation Center for Individualized Oncology Medicine, Nanjing 210029, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Adult;
Male;
Female;
Middle Aged;
Aged;
Histones/genetics*;
Brain Neoplasms/pathology*;
Proto-Oncogene Proteins B-raf/metabolism*;
Glioma/pathology*;
Astrocytoma/pathology*;
Mutation
- From:
Chinese Journal of Pathology
2023;52(4):376-383
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the clinicopathological characteristics, pathological diagnosis and prognosis of diffuse midline glioma (DMG) with H3K27 alteration in adults. Methods: Twenty cases of H3K27-altered adult DMG diagnosed in the First Affiliated Hospital of Nanjing Medical University were enrolled from 2017 to 2022. All cases were evaluated by clinical and imaging presentations, HE, immunohistochemical staining and molecular genetics; and the relevant literature was reviewed. Results: The ratio of male to female was 1∶1, and the median age was 53 years (range from 25 to 74 years); the tumors were located in the brainstem (3/20, 15%) and non-brainstem (17/20, 85%; three in thoracolumbar spinal cord and one in pineal region). The clinical manifestations were non-specific, mostly dizziness, headache, blurred vision, memory loss, low back pain, limb sensation and/or movement disorders, etc. Microscopically, the tumors showed infiltrative growth, with WHO grade 2 (3 cases), grade 3 (12 cases), and grade 4 (5 cases). The tumors showed astrocytoma-like and oligdendroglioma-like, pilocytic astrocytoma-like and epithelioid-like patterns. Immunohistochemically, the tumor cells were positive for GFAP, Olig2 and H3K27M, and H3K27me3 expression was variably lost. ATRX expression was lost in four cases, p53 was strongly positive in 11 cases. Ki-67 index was about 5%-70%. Molecular genetics showed p. k27m mutation in exon 1 of H3F3A gene in 20 cases; BRAF mutation in two cases: V600E and L597Q mutation in one case each. Follow up intervals ranged from 1 to 58 months, and the survival time for brainstem (6.0 months) and non-brainstem (30.4 months) tumors was significantly different (P<0.05). Conclusions: DMG with H3K27 alteration is uncommonly found in adults, mostly occurs in non-brainstem, and can present in adults of all ages. Owing to the wide histomorphologic features, mainly astrocytic differentiation, routine detection of H3K27me3 in midline glioma is recommended. Molecular testing should be performed on any suspected cases to avoid missed diagnosis. Concomitant BRAF L597Q mutation and PPM1D mutation are novel findings. The overall prognosis of this tumor is poor, with tumors located in the brainstem showing worse outcome.
